Gefticip 250 MG Tablet contains Gefitinib 250mg in an alternative brand formulation, providing the same first-generation EGFR inhibition for EGFR mutation-positive non-small cell lung cancer treatment.

How It Works: Gefitinib blocks EGFR tyrosine kinase activity in tumor cells harboring sensitizing mutations (exon 19 deletions, L858R), stopping the growth signals that drive cancer progression.

Common Uses: EGFR mutation-positive locally advanced or metastatic NSCLC, including patients in Asian populations where EGFR mutations are more prevalent.

Administration: Take once daily at any time with or without food. Consistent timing improves adherence. Swallow whole — do not crush.

Storage: Store below 30°C in a dry location. Keep in original packaging away from moisture and children.

Disclaimer: This product requires a valid prescription. Consult a licensed oncologist before use. This information is for educational purposes only.